Indication
Cervical Intraepithelial Neoplasia Grade 2/3
4 clinical trials
4 products
Clinical trial
An Open-Label, Phase 1/2 Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of RG002 Injection (an mRNA Therapeutic Vaccine) in Subjects With Human Papillomavirus (HPV) 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)Status: Not yet recruiting, Estimated PCD: 2026-10-01
Product
RG002Clinical trial
The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Intraepithelial Neoplasia Grade 2 or Worse in Women Undergoing Conization: Retrospective Cohort StudyStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Product
HPV vaccinationClinical trial
A Feasibility Trial of Alternating Intravaginal Application of 5-Fluorouracil and Imiquimod for Treatment of High-Grade Cervical Squamous Intraepithelial LesionsStatus: Active (not recruiting), Estimated PCD: 2020-11-04
Product
ImiquimodProduct
Topical FluorouracilClinical trial
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod TreatmentStatus: Recruiting, Estimated PCD: 2024-12-01